(2-fluoro-4-methanesulfonyl-phenyl)-[6-(piperidin-4-yloxy)-pyrimidin-4-yl]-amine | 871681-83-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-fluoro-4-methanesulfonyl-phenyl)-[6-(piperidin-4-yloxy)-pyrimidin-4-yl]-amine
• 英文别名: N-(2-fluoro-4-methylsulfonylphenyl)-6-piperidin-4-yloxypyrimidin-4-amine
• CAS: 871681-83-3
• 化学式: C₁₆H₁₉FN₄O₃S
• 分子量: 366.416
• InChiKey: ZNADWZZXZISVBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (2-fluoro-4-methanesulfonyl-phenyl)-[6-(piperidin-4-yloxy)-pyrimidin-4-yl]-amine 、 氯甲酸异丙酯 在 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 1.0h， 以81%的产率得到4-[[6-[(2-fluoro-4 methylsulfonylphenyl)amino]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
  参考文献：
  名称：

  [EN] SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
  [FR] DERIVES D'ARYLE ET D'HETEROARYLE SUBSTITUES TENANT LIEU DE MODULATEURS DU METABOLISME ET PREVENTION ET TRAITEMENT DE TROUBLES ASSOCIES

  摘要：

  公开号：

  WO2005121121A3

文献信息

• Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
  申请人：Jones Robert M.

  公开号：US20090036434A1

  公开（公告）日：2009-02-05

  The present invention relates to certain substituted aryl and heteroaryl derivative of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

  本发明涉及公式（I）的某些取代芳基和杂环芳基衍生物，它们是代谢调节剂。因此，本发明的化合物在代谢相关疾病和并发症的治疗中是有用的，如糖尿病和肥胖症。
• SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP1756084A2

  公开（公告）日：2007-02-28
• USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP2004157A2

  公开（公告）日：2008-12-24
• GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto
  申请人：Chu Zhi-Liang

  公开号：US20090270422A1

  公开（公告）日：2009-10-29

  The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. A GPR119 receptor agonist and the combination of a GPR119 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual.
• GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto
  申请人：Chu Zhi-Liang

  公开号：US20100190750A1

  公开（公告）日：2010-07-29

  The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. A GPR119 receptor agonist and the combination of a GPR119 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual.